Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document 8318954
Transcript
epiCaPture A New Urine Test to Detect High-‐risk Prostate Cancer Overview – What is epiCaPture? A urine test that detects the presence of prostate cancer cells, epiCaPture measures biochemical changes at 6 genes and identifies which men need a biopsy to diagnose prostate cancer using an algorithm to assess prostate cancer aggressiveness. What Problems does it Solve/Advantages? How epiCaPture works Traditional needle biopsies may miss cancer foci resulting in repeat PSA tests and invasive biopsies. 25-45 million PSA tests are performed worldwide per annum. A high false-positive rate leads to unnecessary biopsies, which are expensive and cause trauma and anxiety to patients. epiCaPture alleviates problems with early detection of prostate cancer 1. Improved tumour-‐specificity over PSA -‐ Reduce need for unnecessary invasive biopsy 2. Selec>ve detec>on of high-‐risk disease -‐ Alleviate over-‐treatment of low-‐risk disease -‐ Aid risk-‐stra>fica>on for selec>on of subsequent treatments or surveillance Diagnos>cs 3. Provides informa>on about the molecular biology of the disease December 2014 Market IP Status Priority Patent Filed EP14199999 Opportunity Research collabora>on Available to license Researcher(s) A Tuzova L DeBarra S O’Meachair A Perry Technology and Patent Status Contact Dr. Gordon EllioM, The opportunity This technology is currently undergoing valida>on in a large independent cohort of men. • Post-‐DRE urine sediment analysis Case Manager, Transla>onal Sciences • Real-‐>me PCR [email protected] • Bisulfite conversion of DNA +353 1 896 4151 • Quan>ta>ve DNA methyla>on analysis of 6 gene loci • Patent applica>on submiMed Reference: AP02-‐490-‐01
